Onconetix, Inc.

Onconetix, Inc. is a commercial-stage biotechnology company established in 2018 and headquartered in Cincinnati, Ohio. The company focuses on the research, development, and commercialization of innovative solutions within men's health and oncology.

Its core product portfolio includes Proclarix®, an in vitro protein-based blood diagnostic test for prostate cancer, which is approved for sale in the European Union and is anticipated to be marketed in the U.S. as a lab-developed test through a license agreement with Labcorp. Onconetix also offers ENTADFI®, an FDA-approved oral therapeutic for the treatment of benign prostatic hyperplasia (BPH). The company holds a license agreement with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test.

In recent developments, Onconetix announced in February 2026 its definitive agreement to acquire Realbotix LLC, an AI-powered humanoid robotics company, with the transaction expected to close in the second half of 2026. David White was appointed Chief Executive Officer in March 2026. To maintain compliance with Nasdaq's minimum bid price requirement, the company enacted a 1-for-10 reverse stock split effective May 21, 2026. Onconetix continues to report progress on its Proclarix diagnostic test, including new peer-reviewed publications and the initiation of a U.S. validation study in Q1 2026.